Ken Griffin Igm Biosciences, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$6.28 - $17.68 $75,360 - $212,160	12,000 Added 126.32%	21,500 $355,000
Q2 2024 Aug 14, 2024	SELL	$6.51 - $11.47 $3,255 - $5,735	-500 Reduced 5.0%	9,500 $65,000
Q1 2024 May 15, 2024	SELL	$8.68 - $17.36 $9,548 - $19,096	-1,100 Reduced 9.91%	10,000 $96,000
Q4 2023 Feb 14, 2024	SELL	$3.94 - $8.79 $3,152 - $7,031	-800 Reduced 6.72%	11,100 $92,000
Q3 2023 Nov 14, 2023	SELL	$6.66 - $10.64 $65,934 - $105,336	-9,900 Reduced 45.41%	11,900 $99,000
Q2 2023 Aug 14, 2023	BUY	$8.86 - $14.0 $167,454 - $264,600	18,900 Added 651.72%	21,800 $201,000
Q1 2023 May 15, 2023	SELL	$13.74 - $25.76 $120,912 - $226,688	-8,800 Reduced 75.21%	2,900 $39,000
Q4 2022 Feb 14, 2023	BUY	$15.45 - $26.02 $180,765 - $304,434	11,700 New	11,700 $199,000

20.7M

68K

52.2K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $258M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.